vs
Massimo Group（MAMO）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Massimo Group的1.7倍（$35.5M vs $21.0M），Massimo Group净利率更高（9.5% vs -304.2%，领先313.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 15.7%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -16.5%）
Massimo Dutti是一家西班牙高端服装零售商，主打开司米与羊毛制品，创立于1985年，现隶属于西班牙跨国集团Inditex。Inditex集团同时拥有Zara、Pull&Bear等知名服装品牌。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
MAMO vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.7倍
$21.0M
营收增速更快
RXRX
高出666.1%
15.7%
净利率更高
MAMO
高出313.7%
-304.2%
两年增速更快
RXRX
近两年复合增速
-16.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0M | $35.5M |
| 净利润 | $2.0M | $-108.1M |
| 毛利率 | 41.5% | 59.8% |
| 营业利润率 | 13.1% | -304.8% |
| 净利率 | 9.5% | -304.2% |
| 营收同比 | 15.7% | 681.7% |
| 净利润同比 | 215.0% | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAMORXRX
| Q4 25 | $21.0M | $35.5M | ||
| Q3 25 | $17.0M | $5.2M | ||
| Q2 25 | $18.9M | $19.2M | ||
| Q1 25 | $14.9M | $14.7M | ||
| Q4 24 | $18.2M | $4.5M | ||
| Q3 24 | $25.6M | $26.1M | ||
| Q2 24 | $35.4M | $14.4M | ||
| Q1 24 | $30.2M | $13.8M |
净利润MAMORXRX
| Q4 25 | $2.0M | $-108.1M | ||
| Q3 25 | $1.5M | $-162.3M | ||
| Q2 25 | $77.7K | $-171.9M | ||
| Q1 25 | $-2.1M | $-202.5M | ||
| Q4 24 | $-1.7M | $-178.9M | ||
| Q3 24 | $-2.5M | $-95.8M | ||
| Q2 24 | $2.8M | $-97.5M | ||
| Q1 24 | $3.2M | $-91.4M |
毛利率MAMORXRX
| Q4 25 | 41.5% | 59.8% | ||
| Q3 25 | 42.0% | -183.8% | ||
| Q2 25 | 36.3% | -4.9% | ||
| Q1 25 | 28.4% | -48.0% | ||
| Q4 24 | 19.6% | -181.4% | ||
| Q3 24 | 27.2% | 53.7% | ||
| Q2 24 | 32.5% | 36.2% | ||
| Q1 24 | 34.7% | 19.1% |
营业利润率MAMORXRX
| Q4 25 | 13.1% | -304.8% | ||
| Q3 25 | 10.5% | -3327.6% | ||
| Q2 25 | 0.8% | -916.8% | ||
| Q1 25 | -18.2% | -1297.9% | ||
| Q4 24 | -15.4% | -4042.4% | ||
| Q3 24 | 1.2% | -377.1% | ||
| Q2 24 | 10.1% | -697.4% | ||
| Q1 24 | 13.2% | -698.4% |
净利率MAMORXRX
| Q4 25 | 9.5% | -304.2% | ||
| Q3 25 | 9.0% | -3135.3% | ||
| Q2 25 | 0.4% | -894.2% | ||
| Q1 25 | -14.0% | -1373.3% | ||
| Q4 24 | -9.5% | -3935.5% | ||
| Q3 24 | -9.8% | -367.5% | ||
| Q2 24 | 8.0% | -676.6% | ||
| Q1 24 | 10.6% | -662.4% |
每股收益（稀释后）MAMORXRX
| Q4 25 | $0.05 | $-0.17 | ||
| Q3 25 | $0.04 | $-0.36 | ||
| Q2 25 | $0.00 | $-0.41 | ||
| Q1 25 | $-0.05 | $-0.50 | ||
| Q4 24 | $-0.05 | $-0.56 | ||
| Q3 24 | $-0.06 | $-0.34 | ||
| Q2 24 | $0.07 | $-0.40 | ||
| Q1 24 | $0.08 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.8M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $23.7M | $1.1B |
| 总资产 | $51.4M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资MAMORXRX
| Q4 25 | $5.8M | $743.3M | ||
| Q3 25 | $2.6M | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | $3.0M | $500.5M | ||
| Q4 24 | $10.2M | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务MAMORXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益MAMORXRX
| Q4 25 | $23.7M | $1.1B | ||
| Q3 25 | $21.7M | $1.0B | ||
| Q2 25 | $20.2M | $919.1M | ||
| Q1 25 | $19.9M | $933.9M | ||
| Q4 24 | $21.7M | $1.0B | ||
| Q3 24 | $22.5M | $524.6M | ||
| Q2 24 | $24.7M | $584.4M | ||
| Q1 24 | $18.1M | $401.2M |
总资产MAMORXRX
| Q4 25 | $51.4M | $1.5B | ||
| Q3 25 | $44.4M | $1.4B | ||
| Q2 25 | $45.9M | $1.3B | ||
| Q1 25 | $46.4M | $1.3B | ||
| Q4 24 | $54.9M | $1.4B | ||
| Q3 24 | $57.1M | $726.5M | ||
| Q2 24 | $49.9M | $775.9M | ||
| Q1 24 | $47.3M | $557.8M |
负债/权益比MAMORXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 2.01× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流MAMORXRX
| Q4 25 | $4.0M | $-46.1M | ||
| Q3 25 | $633.2K | $-117.4M | ||
| Q2 25 | $-1.4M | $-76.4M | ||
| Q1 25 | $-3.3M | $-132.0M | ||
| Q4 24 | $9.1M | $-115.4M | ||
| Q3 24 | $4.7M | $-59.2M | ||
| Q2 24 | $-6.5M | $-82.2M | ||
| Q1 24 | $-637.0K | $-102.3M |
自由现金流MAMORXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | $9.0M | $-116.7M | ||
| Q3 24 | $4.6M | $-63.8M | ||
| Q2 24 | $-6.7M | $-83.4M | ||
| Q1 24 | $-741.4K | $-109.0M |
自由现金流率MAMORXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | 49.7% | -2567.7% | ||
| Q3 24 | 18.1% | -244.6% | ||
| Q2 24 | -19.0% | -578.5% | ||
| Q1 24 | -2.5% | -789.9% |
资本支出强度MAMORXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | 0.2% | 28.6% | ||
| Q3 24 | 0.3% | 17.5% | ||
| Q2 24 | 0.7% | 8.2% | ||
| Q1 24 | 0.3% | 48.2% |
现金转化率MAMORXRX
| Q4 25 | 2.01× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | -17.92× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.30× | — | ||
| Q1 24 | -0.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
